02/18/2025
5:07 AM | Revance Therapeutics (Filer)
| Form 15-12G | |
02/12/2025
6:57 AM | Revance Therapeutics (Filer)
| Form S-8 POS | |
02/12/2025
6:58 AM | Revance Therapeutics (Filer)
| Form S-8 POS | |
02/12/2025
7:00 AM | Revance Therapeutics (Filer)
| Form S-8 POS | |
02/12/2025
7:01 AM | Revance Therapeutics (Filer)
| Form S-8 POS | |
02/12/2025
7:02 AM | Revance Therapeutics (Filer)
| Form S-8 POS | |
02/12/2025
7:03 AM | Revance Therapeutics (Filer)
| Form S-8 POS | |
02/12/2025
7:04 AM | Revance Therapeutics (Filer)
| Form S-8 POS | |
02/12/2025
7:06 AM | Revance Therapeutics (Filer)
| Form S-8 POS | |
02/12/2025
7:08 AM | Revance Therapeutics (Filer)
| Form S-8 POS | |
02/12/2025
7:16 AM | Revance Therapeutics (Filer)
| Form S-8 POS | |
Get the Latest News and Ratings for RVNC and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter. |
02/12/2025
6:50 AM | Revance Therapeutics (Filer)
| Form POSASR | |
02/12/2025
6:52 AM | Revance Therapeutics (Filer)
| Form S-8 POS | |
02/12/2025
6:53 AM | Revance Therapeutics (Filer)
| Form S-8 POS | |
02/12/2025
6:54 AM | Revance Therapeutics (Filer)
| Form S-8 POS | |
02/12/2025
6:55 AM | Revance Therapeutics (Filer)
| Form S-8 POS | |
02/11/2025
11:16 AM | JPMORGAN CHASE & CO (Filed by)
JPMORGAN CHASE & CO (Filed by)
Revance Therapeutics (Subject)
| Form SCHEDULE 13G | |
02/06/2025
7:06 PM | Gangolli Julian S (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/06/2025
5:19 PM | GLAZER CAPITAL, LLC (Filed by)
Revance Therapeutics (Subject)
| Form SCHEDULE 13G | |
02/06/2025
2:45 PM | Revance Therapeutics (Issuer)
Russell Angus C. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/06/2025
2:48 PM | Nolet Chris (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/06/2025
2:49 PM | Beraud Jill (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/06/2025
2:49 PM | Coric Vlad (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/06/2025
8:22 AM | Nasdaq Stock Market LLC (Filed by)
Revance Therapeutics (Subject)
| Form 25-NSE | |
02/06/2025
7:59 AM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/05/2025
6:53 PM | Moxie Dwight (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/05/2025
6:53 PM | Revance Therapeutics (Issuer)
Schilke Tobin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/05/2025
6:53 PM | Foley Mark J (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/05/2025
7:41 AM | Revance Therapeutics (Subject)
| Form SC 14D9/A | |
02/05/2025
7:14 AM | Crown Laboratories, Inc. (Filed by)
Revance Therapeutics (Subject)
| Form SC TO-T/A | |
01/31/2025
7:08 AM | Crown Laboratories, Inc. (Filed by)
Revance Therapeutics (Subject)
| Form SC TO-T/A | |
01/31/2025
6:46 AM | Revance Therapeutics (Subject)
| Form SC 14D9/A | |
01/30/2025
8:01 AM | Revance Therapeutics (Subject)
Teoxane SA (Filed by)
| Form SCHEDULE 13D/A | |
01/21/2025
7:31 AM | Crown Laboratories, Inc. (Filed by)
Revance Therapeutics (Subject)
| Form SC TO-T/A | |
01/21/2025
7:36 AM | Revance Therapeutics (Subject)
| Form SC 14D9/A | |
01/21/2025
7:11 AM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/17/2025
7:15 AM | Revance Therapeutics (Subject)
| Form SC 14D9/A | |
01/13/2025
3:18 PM | Revance Therapeutics (Subject)
| Form SC 14D9/A | |
01/13/2025
7:44 AM | Crown Laboratories, Inc. (Filed by)
Revance Therapeutics (Subject)
| Form SC TO-T/A | |
01/10/2025
3:52 PM | Beryl Capital Management LLC (Filed by)
Revance Therapeutics (Subject)
| Form SCHEDULE 13G | |
01/07/2025
8:02 PM | Revance Therapeutics (Subject)
| Form SC 14D9/A | |
Nvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry." (Ad) If you missed out on the big boom in Nvidia…
Listen up, because according to Nvidia's own CEO…
Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry. You MUST act before March 17th. |
01/06/2025
8:00 AM | Revance Therapeutics (Subject)
Teoxane SA (Filed by)
| Form SCHEDULE 13D/A | |
01/03/2025
3:33 PM | Foley Mark J (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/03/2025
3:34 PM | Revance Therapeutics (Issuer)
Schilke Tobin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/02/2025
3:36 PM | Revance Therapeutics (Subject)
| Form SC 14D9/A | |
01/02/2025
3:45 PM | Crown Laboratories, Inc. (Filed by)
Revance Therapeutics (Subject)
| Form SC TO-T/A | |
12/19/2024
8:00 AM | Revance Therapeutics (Subject)
Teoxane SA (Filed by)
| Form SCHEDULE 13D/A | |
12/12/2024
7:01 AM | Revance Therapeutics (Subject)
| Form SC 14D9 | |
12/12/2024
6:15 AM | Crown Laboratories, Inc. (Filed by)
Revance Therapeutics (Subject)
| Form SC TO-T | |
12/12/2024
5:01 AM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/09/2024
4:16 PM | Crown Laboratories, Inc. (Filed by)
Revance Therapeutics (Subject)
| Form SC TO-C | |
12/09/2024
8:24 AM | Revance Therapeutics (Subject)
| Form SC14D9C | |
12/09/2024
8:17 AM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/05/2024
3:23 PM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/03/2024
7:27 AM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/29/2024
5:02 AM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/26/2024
5:01 AM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/01/2024
8:24 AM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/31/2024
12:20 PM | FRANKLIN RESOURCES INC (Filed by)
Revance Therapeutics (Subject)
| Form SCHEDULE 13G/A | |
10/25/2024
7:49 PM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/23/2024
6:17 PM | GIC Private Ltd (Filed by)
Revance Therapeutics (Subject)
| Form SC 13G/A | |
10/18/2024
8:29 AM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/07/2024
9:08 AM | Capital World Investors (Filed by)
Revance Therapeutics (Subject)
| Form SC 13G/A | |
10/04/2024
6:32 AM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/23/2024
6:15 AM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/16/2024
4:01 PM | Beryl Capital Management LLC (Filed by)
Revance Therapeutics (Subject)
| Form SC 13G | |
09/09/2024
9:40 AM | Capital World Investors (Filed by)
Revance Therapeutics (Subject)
| Form SC 13G/A | |
09/05/2024
4:27 PM | Revance Therapeutics (Subject)
| Form SC14D9C | |
09/05/2024
3:45 PM | Crown Laboratories, Inc. (Filed by)
Revance Therapeutics (Subject)
| Form SC TO-C | |
08/13/2024
8:29 AM | Crown Laboratories, Inc. (Filed by)
Revance Therapeutics (Subject)
| Form SC TO-C | |
08/12/2024
4:18 PM | Revance Therapeutics (Subject)
| Form SC14D9C | |
08/12/2024
8:20 AM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/09/2024
8:00 AM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/08/2024
3:34 PM | Revance Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
07/02/2024
4:47 PM | Revance Therapeutics (Issuer)
Schilke Tobin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/02/2024
4:47 PM | Foley Mark J (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/09/2024
3:08 PM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/03/2024
7:42 AM | Beraud Jill (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/03/2024
7:43 AM | Coric Vlad (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/03/2024
7:44 AM | Gangolli Julian S (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/03/2024
7:45 AM | Kolaja Carey OConnor (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/03/2024
7:46 AM | Nolet Chris (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/03/2024
7:47 AM | Revance Therapeutics (Issuer)
Russell Angus C. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/03/2024
7:47 AM | Revance Therapeutics (Issuer)
Ware Olivia C (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/17/2024
3:34 PM | Jordan Erica (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/09/2024
12:17 PM | JPMORGAN CHASE & CO (Filed by)
JPMORGAN CHASE & CO (Filed by)
Revance Therapeutics (Subject)
| Form SC 13G/A | |
03/19/2024
5:43 PM | Foley Mark J (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/19/2024
5:44 PM | Revance Therapeutics (Issuer)
Schilke Tobin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/19/2024
5:44 PM | Moxie Dwight (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/19/2024
5:45 PM | Revance Therapeutics (Issuer)
Sjuts Dustin S (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/18/2024
5:16 AM | Revance Therapeutics (Subject)
Sjuts Dustin S (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
Nvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry." (Ad) If you missed out on the big boom in Nvidia…
Listen up, because according to Nvidia's own CEO…
Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry. You MUST act before March 17th. |
03/18/2024
5:10 AM | Moxie Dwight (Reporting)
Revance Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/18/2024
5:13 AM | Revance Therapeutics (Subject)
Schilke Tobin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/08/2024
3:33 PM | Foley Mark J (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/05/2024
4:08 PM | Revance Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/04/2024
4:33 PM | Moxie Dwight (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/04/2024
3:44 PM | Revance Therapeutics (Issuer)
Schilke Tobin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/04/2024
3:33 PM | Foley Mark J (Reporting)
Revance Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/04/2024
5:39 AM | Revance Therapeutics (Filer)
| Form 424B5 | |
02/29/2024
3:32 PM | Hollander David (Reporting)
Revance Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
